Here you can find selected articles and reports about Dr. Seibt Genomics.
Russian guests are interested in Deluxe Whole Genome Sequencing
Prof. Dr. Thomas Gasser and Dr. Benjamin Seibt welcome the Russian guests in the Beta Klinik. There is an ongoing international interest in Bonn’s first class medical care and exclusive genetic services. Dr. Seibt presents the “Deluxe Whole Genome Sequencing” with a focus on pharmacogenomics and nutrigenomics. Prof. Dr. Gasser guides the guests from Moscow through the international private Beta Klinik, which is already celebrating its 10th anniversary.
Young pharmacists become involved
What do genes have to do with drug efficacy, how do I give a really good speech and are there any relevant political news for pharmacists? The “Apothekerkammer Westfalen-Lippe” invites young pharmacists to Dortmund to learn about these interesting topics and enjoy a delicious brunch. Coach Anja Keck, AKWL board member Christine Weber and guest speaker Dr. Benjamin Seibt, founder of Dr. Seibt Genomics, (see picture from left to right) will be the key speakers of this Sunday morning.
Dr. Seibt Genomics receives award from Stilpunkte
Dr. Seibt Genomics receives an award for 2018/2019 from the renowned lifestyle magazine “Stilpunkte”. Dr. Seibt Genomics was evaluated according to the strict Stilpunkte criteria and now officially belongs to the best locations in Germany.
Dr. Seibt lectures at Qatar University
In the beginning of November, Dr. Seibt travels to Doha to lecture at the “College of Pharmacy” and the “College of Business and Economics” of Qatar University. There, he lectures on pharmacogenomics and shares his experience as an innovative and internationally acting entrepreneur. During his stay, Dr. Seibt also has conversations with the dean of Pharmacy, Dr. Mohammad Diab, the vice-president, Prof. Egon Toft, and the president, Dr. Hassan Al-Derham, of Qatar University.
Read the latest issue of medintern
Ivacaftor for the personalized treatment of cystic fibrosis. Ivacaftor is a CFTR potentiator that is used for the targeted treatment of cystic fibrosis. Ivacaftor induces a prolonged opening of chloride channels encoded by the CFTR gene. This leads to a significant improvement of lung function and to a significant reduction of pulmonary exacerbations.
Read the full article by Dr. Seibt plus the article Risk for HLA genotypes during therapy with Carbamazepine und Oxcarbazepine in the current issue of medintern from 03/18.
Exclusive DNA analyses for Russia
Moscow and Saint Petersburg are the two largest and most important cities of Russia, in which almost 10% of the Russian population live. Dr. Seibt Genomics had already recognized some time ago that the exclusive DNA analyses like „Deluxe Whole Genome Sequencing“ are met with particular interest in Russia. Because health and prevention are very important for the Russian people, Dr. Seibt personally travels to Moscow and Saint Petersburg.
First annual meeting of PurinesDX in Dublin
Dr. Björn Schmitt travels to Dublin to participate in the first annual meeting of PurinesDX in Dublin. Here, the involved PhD students discuss their first promising results with the involved project partners. PurinesDX is a scientific project that has received funding from the European Union's Horizon 2020 research and innovation program. The project is focussed on neurodegenerative disorders, like Alzheimer's, amyotrophic lateral sclerosis (ALS) and Huntington's disease, but also includes mental disorders, like depression, schizophrenia and epilepsy. Dr. Seibt Genomics supports the project as a partner organization by providing its expertise in the identification of genetic risk factors.
BioRiver Boost! 2018 at the Bayer research center in Wuppertal
During the annual contest BioRiver Boost! innovative life science start-ups from the Rhineland present their trendsetting ideas. The founders and start-ups profit from the contact to market leaders, specific advice and a broad network. On October the 10th, Dr. Benjamin Seibt gives a talk at the Bayer research center in Wuppertal as a former winner of the „BioRiver Boost! 2016“ award, which he received for his company Dr. Seibt Genomics. Afterwards, the new life science founders will give their exciting pitches.
Federal Minister for Health Jens Spahn talks on the Deutscher Apothekertag in Munich
Around 300 delegated pharmacists from all 17 county chambers and 17 county associations have assembled in Munich on this year's „Deutscher Apothekertag“ to discuss their policital situation and future plans. Dr. Benjamin Seibt attended as a delegate for the Apothekerkammer Nordrhein, which he has been for 10 years. Federal Minister for Health Jens Spahn (see the photo) was invited as a guest and gave an interesting speech. Afterwards, he discussed future aims and their timely implementation together with the pharmacists.
Hamburger Adler fellows are interested in pharmakogenomics
The Privilegierte Adler Apotheke in Hamburg of pharmacist Ms. Heike Gnekow (see photo) and Mr. Holger Gnekow awards the Adler scholarship twice a year to extraordinary and dedicated pharmaceutical students. The scholarship includes a literature allowance as well as several seminars on current, forward-looking pharmaceutical and political subjects. During one of these seminars on October the 6th, Dr. Benjamin Seibt gave a talk on the subjects pharmacogenomics and nutrigenomics.
Baden-Baden Entrepreneur Talks in Bonn
Prof. Dr. Thomas Gasser of the Beta Klinik and Dr. Benjamin Seibt both give interesting talks during a meeting of the „Baden-Baden Entrepreneur Talks“ (BBUG) in the Telekom Design Gallery in Bonn. An exciting discussion develops on the topics "human machine interface" and "genetic revolution". The BBUG has around 130 members, mainly companies from the industrial sector as well as banking, insurance, traide, traffic, media and communications companies. DAX 30 companies and medium-sized global players equally send their top executives to provide the future generation of business leaders with a broad perspective on their role in economy and society.
Beta Blog: Dr. Benjamin Seibt explains the gene diet and the genetic nutrition in the Top-Magazin
A healthy lifestyle is important to stay healthy and fit, and especially the nutrition plays a key role in this. Dr. Benjamin Seibt, CEO of the genomics company Dr. Seibt Genomics located in Bonn, explains the gene diet and the identification of the ideal genetic nutrition his compay offers in the current autumn edition of the Top-Magazin Bonn. Click here to read more.
TOP Magazin Bonn: The answer lies in our genes
TOP magazine Bonn reports in its current issue not only on the TOP summer night, but also on the gene diet from Dr. med. Seibt Genomics. A healthy diet should be the ultimate goal since this will form the basis for a fulfilling life lasting into old age. However, heavy overweight and obesity is becoming more and more of a serious problem in industrialized countries. Here you can read the full article.
The Russian lifestyle magazine
Dr. Seibt Genomics offers genetic lifestyle analysis in the Russian edition of the tourist lifestyle magazine "Travel, Shopping & Health Guide Rhineland” for visitors to the Rhineland. The magazine offers exciting information on topics such as culture & customs in the Rhineland as well as on regulations in public life within Germany. There are also recommendations on doctors, clinics, shopping opportunities, hotels, restaurants and excursions in and around Bonn. Click on the image to open the magazine for free.
General-Anzeiger: The Beta Clinic is celebrating ten years at the Bonner Bogen
The clinic has grown from initially three to 60 doctors, from 1,500 to 13,000 square meters - and even after its 10th anniversary the Beta Clinic in Bonn-Beuel is still continuing to grow. The Bonner Generalanzeiger reported on the visit of Bonn’s Mayor Ashok Sridharan to the Beta Klinik. Here you can read the full article.
Beta Blog: The Mayor of Bonn congratulates the Beta Clinic to mark its tenth anniversary
The Beta Clinic is celebrating its 10th anniversary this year. Bonn's Mayor Ashok Sridharan visited the private clinic on the Rhine to get his own impressions of the development and medical expertise at the Bonner Bogen. Here Mr Sridharan sums it up: “It is important to emphasize at this point that since its founding in Bonn, the company has made a great name for itself in the region as well as abroad. The Beta Clinic consolidates Bonn's reputation as an excellent health location." Click here for the full article in the Beta Blog.
Video of the EU project PurinesDx
The newly published video of PurinesDx provides an excellent overview of the entire scientific programme which is supported by the European Union within the framework of the Marie Skłodowska-Curie program. As a member of the consortium, Dr. Seibt amongst others explains the challenges and perspectives in the video.
The Beta Blog reports on genetic nutrition
Knowing what foods are good for you. Dr. Seibt Genomics provides an easy way to optimally nourish your body with its genetic nutrition product. A small saliva sample is enough to create an individual gene profile which will then provide information about which nutrients and food your body needs and in which amounts. And of course also the foods that are best avoided. The full article is here.
Visit from Brazil in Bonn
The visit of Dr. Seibt Genomics for initiating business under the auspices of the Federal Ministry of Economy and Energy to Brazil in June 2018 was a resounding success. Mrs. Svenja Kalteich, from the company Brazil Pathways, then travelled from Brazil to Dr. Seibt Genomics to take a look at the labs and the company. Here the business initiation trip and its outcome could be discussed and talked over again in finer detail.
Podcast on the topic "Genetic Testing" with MD Gerrit Keferstein
Gerrit Kieferstein is a medical doctor specializing in Performance & Functional Medicine. He visited Dr. Benjamin Seibt in Bonn and interviewed him on the subject of "Genetic Testing". The exciting podcast from the series "Order & Chaos of Human Potential" can be found here. The two experts discussed how genetic analyzes can be used to assess the individual risk of disease, individualize drug dosages, and to find a genetically optimized diet.
South Koreans visiting Dr. Seibt Genomics in Bonn
On the business initiation trip under the auspices of the Federal Ministry of Economic Affairs and Energy to Tokyo in June 2018, Dr. Seibt met up with the South Korean Youngjin locally. Youngjin then traveled together with the successful businessman Youngil from Seoul to Dr. Seibt Genomics in Bonn. Detailed discussions on innovative businesses and cooperations were then held.
Beta Blog: Healthy and slim thanks to the gene diet
Dietary myths stubbornly persist as much as excess weight around the hips also does. A targeted view of one's own genes can quickly reveal the nutrition and dietary type concealed within you. Dr. Seibt Genomics offers a test procedure that examines selected 'weight genes' and determines which foods and nutrients the body needs and in which dosages to stay healthy and fit for longer. Read more here.
Prof. Dr. Daniela Gündisch from Hawaii on a visit to Bonn
In July 2018, Prof. Dr. Daniela Gündisch visited Dr. Seibt Genomics in Bonn (see photo). She is researching new ligands for the nicotinic acetylcholine receptor that play a central role in the central nervous system at the University of Hawaii at Hilo in the Department of Pharmaceutical Sciences. Prof. Gündisch reported that a separate chair of pharmacogenomics will soon be set up at the University of Hawaii. In the USA, pharmacogenomics already has a very high priority.
The Arab lifestyle magazine
Dr. Seibt Genomics offers genetic lifestyle analysis in the Arabic language edition of the tourism lifestyle magazine "Travel, Shopping and Health Guide Rhineland" for visitors to the Rhineland. The magazine offers interesting information on topics such as culture and customs in the Rhineland as well as regulations in public life in Germany. There are also recommendations on doctors, clinics, shopping opportunities, hotels, restaurants and excursions in and around Bonn. Click on the image to open the magazine for free.
Read the latest issue of MedIntern
Clopidogrel should only be taken after a genetic CYP2C19 test. Clopidogrel is a platelet aggregation inhibitor of the P2Y12 antagonist group which is used to prevent atherothrombotic events. Clopidogrel is a prodrug that is metabolized by the liver enzyme cytochrome P450 2C19 (CYP2C19) into its active metabolite. If the function of CYP2C19 is reduced or completely blocked due to a genetic variation, this can lead to a very high risk for e.g. ACS, PCI, heart attack or stroke in patients taking clopidogrel.
Read the full article by Dr. Seibt in the current issue of MedIntern from 2/18.
From Japan to Brazil
In June 2018 Dr. Seibt Genomics traveled around the world from Tokyo to New York to Sao Paulo. In Brazil there was a business initiation trip organized by the Federal Ministry of Economy and Energy. Dr. Seibt made a presentation in front of a very open-minded audience of the company’s innovations in the fields of pharmacogenomics and nutrigenomics (see left photo). There were also many highly positive discussions with potential business partners. During the course of this trip Dr. Seibt met up with the prominent Brazilian geneticist and pharmacist Francine Campagnari (see right photo).
Business initiation trip to Japan
As part of a business delegation, Dr. Seibt Genomics traveled with the Federal Ministry of Economic Affairs and Energy to Tokyo/Japan. In addition to a reception at the German Embassy in Tokyo, discussions with potential business partners were the main focus. Here, among others, Dr. Seibt met up with Youngjin from South Korea (see left photo), who traveled especially from Seoul for this meeting. The first talks were then held about an in-depth cooperation.
The official launch of PurinesDX in Dublin
In Dublin, all the participating doctoral students, university professors and industrial partners from all over Europe met at the launch of PurinesDX for the very first time. PurinesDX is a scientific project that is is sponsored by the European Union within the context of the Horizon 2020 program. It deals particularly with neurodegenerative diseases such as Alzheimer's, Amyotrophic Lateral Sclerosis (ALS) and Huntington's Disease, as well as with depression, schizophrenia and epilepsy. Dr. Seibt Genomics focuses on Alzheimer's disease and antidepressants in the PurinesDX project.
Pharmacist wooing “genetic scaredy cats”
The Apotheke Adhoc has been closely following Dr. Seibt Genomics since its founding and has reported over and over again on the new challenges and the great progress made by the innovative start-up from the Bonner Bogen.
Click here to read more about the interview with Dr. Benjamin Seibt:
In no other country in the world are people more afraid of genetic diagnostics than in Germany - according to the pharmacist Benjamin Seibt. He founded the company Dr. Seibt Genomics in Bonn in 2014. Among other things, his lab can be used to find out how the body metabolizes drugs so that their therapeutic use can then be optimized.
A deeper look into your DNA
The Bonner Generalanzeiger reports on the unique start-up Dr. Seibt Genomics for genetic analysis in Bonn. The article deals intensively with the portfolio of the company. In addition to pharmacogenomics and predictive genetic diagnostics, the limelight is also cast on nutrigenomics. The latter is the discipline in which genetics and diet overlap. This mainly concerns ensuring healthy nutrition and losing weight in consideration of one’s individual genes, as made possible by the gene diet or genetic nutrition.
Continuing education for pharmacists at the University Hospital RWTH in Aachen
The North Rhine Chamber of Pharmacists invites pharmacists to further training at the University Hospital RWTH Aachen on the topic of "Pharmacogenomics: How our genes affect drug effects“. Dr. Seibt talks here about the most modern methods used in drug therapy relating to genetic analysis, in particular with regard to tamoxifen and antidepressants, and how this useful DNA test can be used in medical practice and made accessible to the patient.
Exclusive club evening with Mayor Ashok Sridharan
The Senate Club of the Federal City of Bonn extended an invitation to an exclusive club evening with Mayor Ashok Sridharan on the topic "The status quo and perspectives of the city of Bonn” (see photo). This was an entertaining evening where interesting political topics concerning the city of Bonn were discussed. Dr. Seibt used this event with Mayor Ashok Sridharan to speak about young, innovative, up-and-coming companies from Bonn, as represented by Dr. Seibt Genomics.
Pharmacogenomics - a presentation for pharmacists at the Kameha Grand Hotel
Pharmacist Stefan Fröhling, owner of the Alten Apotheke Godesberg, invited his pharmacist colleagues from the ERFA Group to the modern KAMEHA Grand Hotel in Bonn. Here people met to discuss the future and to plan the next innovative steps. Dr. Benjamin Seibt used this opportunity to deliver an exciting lecture on the topic of "InGENious pharmacogenomics: finally the right drug therapy“.
Expansion of business relations with Qatar
After a successful visit to Doha / Qatar in December 2016 in a business delegation with the Federal Ministry for Economic Affairs and Energy, Dr. Seibt now travelled again to Qatar to expand his business. There he met, among others, Dr. Yousef Al Maslamani (left), Medical Director of the largest state hospital in Qatar, namely the Hamad General Hospital. He also had important discussions with Mr. Hamad Bin Ali Al Hedfa (right photo) who clearly appreciated the beneficial impact of "Deluxe Whole Genome Sequencing" particularly for his population.
Talks in the United Arab Emirates
In Abu Dhabi, Dr. Seibt held important talks with Dr. Sultan on genetic analysis in Arab countries, especially in the United Arab Emirates. The significant demand for genetic analyzes, e.g. for genetic diseases, diabetes and obesity, was talked about in detail. Dr. Seibt Genomics offered its high-quality analyzes to meet this demand.
Dr. Seibt Genomics at the Arab Health trade fair in Dubai
The Arab Health in Dubai is the largest medical trade fair in the Arab world for leading international companies with more than 4,000 exhibitors from around 70 countries and with the attendance of almost 100,000 visitors from approximately 150 countries. Dr. Seibt Genomics as an innovative company in the field of pharmacogenomics, nutrigenomics and genetic diagnostics has also found convertees in the Arab world and is continuously gaining new business partners.
Apothekerverband Bergisch-Land eV extends an invitation to lecture
On Tuesday, 1/23/2018 at 7.45 p.m. a lecture shall be delivered for the purposes of training and in cooperation with the North Rhine Chamber of Pharmacists. The Apothekerverband Bergisch-Land eV invited for a lecture on the topic: InGENious pharmacogenomics - finally the right drug therapy, with the speaker being Dr. Benjamin Seibt. The lecture will be held at the Bergische University of Wuppertal in Gaussstr. 20, Lecture Hall 13, Building L.
Read the latest issue of medintern
Use of 5-fluorouracil without genotyping of DPYD can be fatal. 5-Fluorouracil is a fluoropyrimidine which is used in palliative care, e.g. for colon, rectum, breast, stomach and pancreatic cancer. Some of the patients experience severe side effects which is referred to as 5-fluorouracil toxicity. This may be due to mutations in the DPYD gene, which codes for the enzyme dihydro-pyrimidine dehydrogenase (DPD).
Read the full article by Dr. Seibt in the current issue of medintern from 4/17. In another article entitled Genotyping of CYP2D6 and CYP2C19 in Amitriptyline Therapy, Dr. Seibt describes the influence of genes on therapy with the antidepressant amitriptyline.
Minister Prof. Dr. Pinkwart talking with Dr. Seibt
As part of the event "Legal Framework for the gene scissoring tool CRISPR-Cas in Germany" organized by BioRiver and the Düsseldorf Chamber of Commerce on 11/30/2017, experts discussed with political representatives the development, the potential but also the dangers of the new method. Prof. Dr. Andreas Pinkwart, NRW Minister for Economics, Innovation, Digitization and Energy answered questions from the audience and stated his position on the topic of CRISPR-Cas. Since he wants to positively promote innovative start-ups in NRW, he then held talks with Dr. Seibt. The political problem of the start-up is that statutory health insurance companies only cover genetic tests for pharmacogenomics in exceptional cases, even though the benefit for the patients is proven and the health insurance companies would ultimately save money. Prof. Dr. Pinkwart gladly supports Dr. Seibt Genomics and wants to find a political solution. In the image next to the text from left to right are Prof. Dr. Pinkwart, Prof. Dr. Rubsamen-Schaeff, Dr. Seibt and Dr. Hangen.
Scientific publication released with the participation of Dr. Benjamin Seibt
Bioorganic & Medicinal Chemistry Letters published the article “AMP and adenosine are both ligands for adenosine 2B receptor signaling”. Dr. Seibt researched for this paper during his stay in Australia.
More unique selling points of the pharmacy career - discussion at the Chamber Assembly
In the Chamber Assembly of the North Rhine Chamber of Pharmacists on 11/15/2017 there was an exciting discussion on the future of pharmacy. In the future, pharmacists should find more unique selling points in their profession to clearly highlight their services and to present the value of the pharmacy locally to the population. For example, one pharmacist suggested that pharmacists could even seize the whole field of pharmacogenomics, since it was still a very young field of research. Read the entire article in the Deutsche Apotheker Zeitung.
Gynecology Day for North Rhine - Tamoxifen - Pharmacogenomic analyzes
On the November 18th 2017, Dr. Seibt Genomics exhibited for the second time at the Gynecology Day for North Rhine in Cologne. Here the gynecologist Dr. med. Dr. Norbert Schäfer and the pharmacist Dr. Benjamin Seibt informed about the possibility of pharmacogenomically testing CYP2D6 to optimize the individual dosage of tamoxifen through DNA testing.
Dr. Benjamin Seibt shall deliver a lecture at MEET OSM in Essen on November 22nd, 2017 where he shall talk about laboratory diagnostics. The OSM Group offers innovative solutions for the modern laboratory. The title of the lecture shall be: Know your health: DNA decoding and its effects on laboratory diagnostics! The lecture shall begin at 3.45 p.m. at the Atlantic Congress Hotel in Essen, Germany. The agenda for the event can be found here.
InGENiously interdisciplinary - The Beta Clinic and Dr. Seibt Genomics presenting Medicine 2.0
Under the motto "Medicine 2.0", the Beta Clinic and Dr. Seibt Genomics welcomed around 20 members of the Ambassador Community Bonn from the networking platform Xing for a stimulating informative evening on 10/23/2017. The concept of the "everything under one roof" principle, practiced in the Beta Clinic, was presented to the group by the neurosurgeon and managing director of the Beta Clinic Prof. Dr. med. Thomas Gasser.
The individual compatibility and consumability (metabolization) of drugs, which depends entirely on one's own DNA, was the special focus of the lecture delivered by Dr. med. Benjamin Seibt. The members of the Xing group were visibly impressed by the influence that DNA has on drug compatibility. And they were also shocked at how severe the implications - due to ignorance - that a wrong medication might have for the individual.
You can also read more about how the event progressed on the Beta Clinic blog.
Company directory for in-vitro diagnostics in Germany
The Export Initiative Health Industry (Exportinitiative Gesundheitswirtschaft) has a directory of all German manufacturers of in vitro diagnostics. The English language brochure "Company Directory: In vitro diagnostics" provides an overview of the German in-vitro diagnostics market and the companies that are active there. It is aimed primarily at potential customers and cooperation partners from abroad. Dr. Seibt Genomics always also stands ready to cooperate with foreign partners and is represented in the company list (page 32) for in-vitro diagnostics.
A Bonn company dares to look into the future of diseases
In the Generalanzeiger Bonn an article about Dr.-Ing. Seibt Genomics appeared in the section on Universities and Science. In the worst case, a cancer patient will succumb to his or her disease much too early. And all because of a simple, trifling matter. Since in their case it may just be that the body can not utilize the prescribed drug. One example: For every second woman suffering from breast cancer, the most commonly administered drug does not show the desired effect - with significant side effects, the least of which is hair loss. The drug, which is the first choice for many oncologists, cannot stop the cancer cells because the sufferer does not possess the required enzyme. Read the entire article here.
Innovation, which supports and which is supported
The Beta Clinic reported in its highly readable blog about the scientific project PurineDx which is funded by the European Union. Your Partner Dr. Seibt Genomics is part of this international project. PurinesDx deals in particular with neurodegenerative diseases. The focus is on Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease, as well as depression, schizophrenia and epilepsy. The entire article can be read here.
Dr. Seibt Genomics exploits new markets in India
The Federal Ministry for Economic Affairs and Energy took Dr. Seibt Genomics on a business trip to New Delhi, India in September 2018. There Dr. Seibt delivered an exciting lecture to a group of potential cooperation partners and customers. The potential cooperation partners were visited by Dr. Seibt directly on site (see photo). The trip was rounded off by a visit to a reception hosted by the German Embassy in India.
“PurinesDx" funded by the European Union
As part of the Horizon 2020 program, the European Union funds the scientific project "PurinesDx" through the highly coveted Marie Skłodowska-Curie Grant. In particular, PurinesDx is concerned with neurodegenerative diseases such as Alzheimer's, Amyotrophic Lateral Sclerosis (ALS) and Huntington's Disease, as well as depression, schizophrenia and epilepsy. 14 talented young scientists will experience and research in a very demanding program in at least 3 European countries, attending special workshops before finally writing their doctoral theses. The project was initiated by 9 European universities / institutions and 9 industrial partners from Belgium, Germany, Britain, Ireland, Spain and Hungary. Dr. Seibt Genomics is one of the nine industrial partners that promotes junior talent, offers its expertise and performs genetic analysis, particularly in the areas of antidepressants and Alzheimer's disease.
Medicine 2.0: Meet and Greet Networking Evening in the Beta Clinic in the Bonner Bogen
Next year, the Beta Clinic in the Bonner Bogen will be ten years old. Unified under the roofs of the clinic, around 60 physicians from about 30 departments work in their specialist disciplines and also ensure medical care in a comprehensive operation. As such, the entire treatment, from the initial consultation to the therapy and aftercare, can also be provided under one roof: Short paths and maximum care. A medical offer that people talk about.
The XING Ambassador Community in Bonn wanted to know more about Medicine 2.0 in Bonn and invited its members to a backstage visit to the Beta Clinic. As part of this informative evening, Professor Thomas Gasser, Neurosurgeon and Managing Director of the Beta Clinic and Dr. Benjamin Seibt, specialist pharmacist for drug information and managing director of Dr. Seibt Genomics, presented the opportunities for modern medicine at the Bonner Bogen.
TOP Magazine: Networks by the minute
Speed dating meets bowling: Top Bonn "hooks up" entrepreneurs during a networking evening of a breathtaking nature. How much information can be fitted into just four minutes? Just enough to briefly introduce your own company and find potential points of interaction with your counterpart! This is then followed by a brief exchange of business cards before moving on to the next conversation partner. Here you can find the full article.
Phone-in organized by Deutschlandfunk - malignant diseases in young people
In today's phone-in on Deutschlandfunk a subject was talked about which is not so often dealt with. In Germany, around 15,000 young people between the ages of 18 and 39 years get cancer every year. About 80 percent can be cured, but the diagnosis of "cancer" is nevertheless an enormous burden. Because it meets those affected in a phase of life where other things should be the main focus. The phone-in was moderated by Martin Winkelheide. At the end of the show pharmacogenomics was also addressed (38 min.), with Dr. Seibt pointing out the importance of testing the individual effectiveness of tamoxifen in breast cancer patients over the phone.
Bonn is also applying to host the headquarters of the European Medicines Agency
Under the slogan 'Closer to Europe', the Federal Republic of Germany applies to the European Union (EU) with its Federal City of Bonn, located in the European Rhine region, to be the headquarters of the European Medicines Agency (EMA). Five arguments that support Bonn as the future headquarters of the EMA include: 1. Bonn is situated in the center of Europe and is easily accessible. 2. The European Rhine region is an important health location. 3. Bonn is an important location for science and medicine. 4. Bonn is an international city. 5. Bonn can offer a high quality of life. Dr. Seibt Genomics can only reinforce these truths and wish the Federal City of Bonn great success in its endeavors to apply.
Beta Plus Obesity
The interdisciplinary obesity center of the Beta Klinik offers overweight patients in Bonn a competent and experienced team which provides all round advice and individualized treatment. In addition to intensive consultation, comprehensive diagnostics and individualized therapy, the Beta Plus obesity package also offers only short routes between the various specialist departments. Dr. Seibt Genomics is part of this competence team and uses a gene test to assess whether a lipid metabolism disorder might be the underlying cause of obesity. In addition, simply by testing a salivary sample, Dr. Seibt Genomics can determine which diet is the most suitable for each individual.